不同诊断工具的组合允许在单个时间点评估时鉴定无活性的

StephenW

VVIRAL HEPATITIS
A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation
Authors

    First published: 5 October 2016Full publication history
    DOI: 10.1111/liv.13246View/save citation
    Cited by: 1 article

    Article has an altmetric score of 2

    Handling Editor: Alessio Aghemo
    Funding information This study had no financial support.

Abstract
Background & Aims

Serial evaluation of hepatitis B virus (HBV) DNA and aminotransferase values is required for identification of inactive HBV carriers (ICs). Recently, HBV surface antigen quantification (qHBsAg) and liver stiffness measurement (LSM) have been proposed as diagnostic tools in chronic HBV infection. The aim of this study was to evaluate the efficacy of HBV DNA quantification, qHBsAg and LSM in diagnosing ICs at a single time point.
Methods

Fifty-seven previously characterized ICs and 90 untreated HBsAg-/anti-HBe-positive patients [49 chronic hepatitis (CH), 41 cirrhosis] were enrolled. HBV DNA ≤2000 IU/mL, LSM ≤6.2 kPa and qHBsAg ≤1000 IU/mL were used as cut-offs to evaluate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy (DA).
Results

Combined HBV DNA quantification and qHBsAg correctly identified 30/57 (52.6%) ICs showing 94% sensitivity, 96% specificity, 98% PPV, 87% NPV and 95% DA. HBV DNA coupled with LSM identified 40/57 (70.2%) ICs showing 97% sensitivity, 97% specificity, 98% PPV, 95% NPV and 97% DA. Combined LSM and qHBsAg identified 33/57 (57.9%) ICs showing 95% sensitivity, 78% specificity, 89% PPV, 89% NPV and 89% DA. The evaluation of the three parameters altogether allowed the identification of 23/57 (40.3%) ICs showing 100% specificity, 96% sensitivity, 100% PPV, 92% NPV and 97% DA. Similar results were obtained when either CH or cirrhotic patients were excluded from the analysis.
Conclusions

Combined evaluation of HBV DNA amount with LSM and/or qHBsAg is a highly reliable tool allowing the identification of a considerable number of HBV ICs at a single time point evaluation.

StephenW

VIRAL HEPATITIS
不同诊断工具的组合允许在单个时间点评估时鉴定无活性的乙型肝炎病毒载体
作者

    首次发布：5十月2016完整的出版历史
    DOI：10.1111 / liv.13246查看/保存引文
    引用：1文章

    文章的得分为2

    处理编辑：Alessio Aghemo
    资助信息本研究没有资金支持。

抽象
背景和目的

乙型肝炎病毒（HBV）的序列评价DNA和氨基转移酶值需要用于鉴定无活性的HBV携带者（IC）。最近，HBV表面抗原定量（qHBsAg）和肝硬度测量（LSM）已被提议作为慢性HBV感染的诊断工具。本研究的目的是评估HBV DNA定量，qHBsAg和LSM在单个时间点诊断ICs的疗效。
方法

招募了57名先前表征的IC和90名未治疗的HBsAg /抗HBe阳性患者[49名慢性肝炎（CH），41名肝硬化]。 HBV DNA≤2000IU / mL，LSM≤6.2kPa和qHBsAg≤1000IU / mL作为临界值，用于评估敏感性，特异性，阳性预测值（PPV），阴性预测值（NPV）和诊断准确度（DA） 。
结果

联合HBV DNA定量和qHBsAg正确识别30/57（52.6％）ICs显示94％灵敏度，96％特异性，98％PPV，87％NPV和95％DA。与LSM偶联的HBV DNA鉴定了40/57（70.2％）IC，其显示97％的灵敏度，97％的特异性，98％的PPV，95％的NPV和97％的DA。联合LSM和qHBsAg鉴定了显示95％敏感性，78％特异性，89％PPV，89％NPV和89％DA的33/57（57.9％）IC。三个参数的评估总共允许鉴定显示100％特异性，96％灵敏度，100％PPV，92％NPV和97％DA的23/57（40.3％）IC。当将CH或肝硬化患者从分析中排除时，获得类似的结果。
结论

综合评价HBV DNA量与LSM和/或qHBsAg是一种高度可靠的工具，允许在单一时间点评估鉴定相当数量的HBV ICs。